Akorn Reviews Future Of Consumer Health Portfolio

Company Considers Divesting Brands For Financial Flexibility

US injectables specialist Akorn has begun to review strategic alternatives for its consumer health business, as the company looks at divesting some of its brands to increase financial flexibility and focus on its prescription generic and branded portfolio.

strategy
Akorn is reviewing strategic alternatives for its consumer health business • Source: Shutterstock

After exiting Chapter 11 protection for which it had filed in 2020, Akorn has announced that it will commence a review of strategic alternatives for its consumer health business. According to the company, which is now operating as a private entity under the legal name, Akorn Operating Company LLC, “this strategic review is a reflection of management’s continued focus on its prescription generic and branded drug portfolio.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By 

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.